Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology
- PMID: 2842480
Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology
Abstract
In the present study we report the results of the EBV-specific antibody response in 30 Italian NPC patients, 20 other head and neck tumor patients and 20 healthy controls. Histopathologically, the tumors were classified as squamous cell carcinoma (WHO 1), nonkeratinizing carcinoma (WHO 2) and undifferentiated carcinoma (WHO 3). Immunofluorescence tests were performed in order to evaluate the antibodies against VCA, EA and the EBV nuclear antigen (EBNA), and the antibody dependent cellular cytotoxicity test was used to detect the EBV specific antibodies against membrane antigens. IgG and IgA antibodies to EBV VCA and IgG antibodies to EA were significantly and consistently higher in the NPC patients than in other patients or controls. Moreover, only the WHO 2 and WHO 3 histological types of NPC resulted associated with EBV. ADCC titers ranging from 1:480 to 1:15360 have been determined; low ADCC titers were prevalent among the VCA-IgA positive donors, while VCA-IgA negative donors presented high ADCC titers. Our results look consistent with other previous results in low-risk and high-risk areas. In conclusion, EBV serology seems to be extremely useful for diagnostic purposes; however, in order to assess a prognostic value of the above markers, a greater number of patients followed for a longer period is needed.
Similar articles
-
The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).Cancer Detect Prev. 1981;4(1-4):307-12. Cancer Detect Prev. 1981. PMID: 6299561
-
Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.Oral Oncol. 2008 Aug;44(8):784-92. doi: 10.1016/j.oraloncology.2007.10.003. Epub 2008 Feb 21. Oral Oncol. 2008. PMID: 18206420
-
Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.J Clin Virol. 2008 Feb;41(2):96-103. doi: 10.1016/j.jcv.2007.09.010. Epub 2007 Nov 19. J Clin Virol. 2008. PMID: 18024156
-
Nasopharyngeal carcinoma and Epstein-Barr virus--associated serologic markers.Ear Nose Throat J. 1990 Apr;69(4):261-7. Ear Nose Throat J. 1990. PMID: 2161732 Review.
-
Monoclonal antibodies in Epstein-Barr virus-related nasopharyngeal carcinoma: prognostic and therapeutic implications.J Exp Pathol. 1987 Summer;3(4):329-33. J Exp Pathol. 1987. PMID: 2842473 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous